文献速递消化系统肿瘤

FOLFOX联合帕尼单抗或单用FOLFOX作为RAS野生型结直肠癌肝转移R0/1切除后附加治疗——PARLIM试验(AIO KRK 0314)

FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314).
PubMed 文献 · Eur J Cancer · 2022-08-12

PARLIM是一项2:1随机、对照、开放标签II期试验,评估RAS野生型结直肠癌肝转移R0/1切除后,在FOLFOX基础上加用帕尼单抗是否改善2年无进展生存(PFS)。实验组70例、对照组36例,2年PFS率分别为35.7%和30.6%,未达到预设的65%活性阈值;PFS(HR 0.83;95%CI 0.52-1.33;P=0.44)和OS(HR 0.70;95%CI 0.34-1.46;P=0.34)呈现有利于帕尼单抗组的趋势,未观察到新的或非预期安全性信号。

要点

  • 实验组12周双周mFOLFOX6联合帕尼单抗后12周帕尼单抗单药,对照组12周双周FOLFOX。
  • 2年PFS率实验组35.7%、对照组30.6%,未达到≥65%的活性阈值。
  • PFS的HR 0.83(95%CI 0.52-1.33;P=0.44)和OS的HR 0.70(95%CI 0.34-1.46;P=0.34)未达统计学显著。

核心结论

  • PARLIM试验未能证明结直肠癌肝转移切除后2年PFS率达到65%。
  • 生存终点的正向趋势可能支持未来评估抗EGFR药物用于肝转移切除后治疗的试验。

研究设计与样本

  • 2:1随机、对照、开放标签、II期试验,纳入RAS野生型结直肠癌R0/1切除后肝转移患者。
  • 实验组接受12周双周mFOLFOX6联合帕尼单抗,随后12周帕尼单抗单药;对照组接受12周双周FOLFOX。
  • 主要终点为随机化后2年PFS率,实验组2年PFS率≥65%视为有效;基于历史数据对照组2年PFS率估计为50%。
  • 试验把握度为80%,α为0.05;全分析集为实验组70例、对照组36例。
  • 试验注册号ClinicalTrials.gov NCT01384994;次要终点包括OS和毒性。

主要发现

  • 2年PFS率实验组为35.7%,对照组为30.6%,主要终点未达到。
  • PFS的HR为0.83(95%CI 0.52-1.33;P=0.44),有利于帕尼单抗组但未达统计学显著。
  • OS的HR为0.70(95%CI 0.34-1.46;P=0.34),有利于帕尼单抗组但未达统计学显著。
  • 肝切除后FOLFOX联合帕尼单抗未观察到新的或非预期安全性信号。

关键数值与推荐

  • 实验组2年PFS率活性阈值≥65%。
  • 基于历史数据对照组2年PFS率估计为50%。
  • 把握度80%,α=0.05。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This trial investigates the addition of panitumumab to chemotherapy with fluorouracil/folinic acid and oxaliplatin (FOLFOX) in a 2:1 randomised, controlled, open-label, phase II trial in RAS wild-type colorectal cancer patients with R0/1-resected liver metastases. EXPERIMENTAL DESIGN: The primary endpoint was progression-free survival (PFS) two years after randomisation. The experimental arm (12 weeks of biweekly mFOLFOX6 plus panitumumab followed by 12 weeks of panitumumab alone) was considered active if the two-year PFS rate was ≥65%. Based on historical data, a two-year PFS rate of 50% was estimated in the control arm (12 weeks of biweekly FOLFOX). The trial was performed with a power of 80% and an alpha of 0.05. Secondary endpoints included overall survival (OS) and toxicity. The trial is registered with ClinicalTrials.gov, NCT01384994. RESULTS: The full analysis set consists of 70 patients (pts) in the experimental arm and 36 pts in the control arm. The primary endpoint was missed with a two-year PFS of 35.7% with FOLFOX plus panitumumab and 30.6% in the control arm. In comparative analyses, trends towards improved PFS (HR 0.83; 95%CI, 0.52-1.33; P = 0.44) and OS (HR 0.70; 95% CI, 0.34-1.46; P = 0.34) were observed in favour of the panitumumab-based study arm. No new or unexpected safety signals were observed with FOLFOX plus panitumumab following liver resection. CONCLUSION: The PARLIM trial failed to demonstrate a two-year PFS rate of 65% after resection of colorectal liver metastases. The positive trends in survival endpoints may support future trials evaluating treatment with anti-EGFR agents after resection of liver metastases.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Modest DP, Karthaus M, Kasper S, et al. FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314). Eur J Cancer. 2022. PMID: 35970102. doi:10.1016/j.ejca.2022.07.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。